Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00214_DB00784_nanopub.RA3EDXCbQZ0XMijLyk-EEUdYA0vf0BTlMPerfWutvyp8w#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00214_DB00784 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00214_DB00784 label "DDI between Torasemide and Mefenamic acid - Mefanamic acid, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Mefanamic acid is initiated, discontinued or dose changed. [drugbank_resource:DB00214_DB00784]" assertion.
- drugbank_resource:DB00214_DB00784 identifier "drugbank_resource:DB00214_DB00784" assertion.
- drugbank_resource:DB00214_DB00784 title "DDI between Torasemide and Mefenamic acid - Mefanamic acid, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Mefanamic acid is initiated, discontinued or dose changed." assertion.
- drugbank:DB00214 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00214_DB00784 assertion.
- drugbank:DB00784 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00214_DB00784 assertion.